![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DRUGMAKERS AGREE PRICE REDUCTIONS FOR ARVS
DRUGMAKERS AGREE PRICE REDUCTIONS FOR ARVS
After two days of negotiations in Buenos Aries, Argentina, drug manufacturers have agreed to reduce the prices of HIV/AIDS therapies used in treatment programmes in Latin America by as much as 15-55%. Under the accord, national spending on anti-retrovirals (ARVs) in the region will be reduced by around 9%, on average. The aim of the talks had been to establish a price cap on ARVs with individual countries then free to negotiate further reductions on an individual basis. However, a number of multinationals refused to participate owing to the continuing threats of a number of governments in the region to break patents on innovative ARVs.
As a result of the agreement, Argentina will gain a 20% reduction on its ARS20mn (US$6.94mn) HIV/AIDS treatment budget, with Brazil able to reduce its wide-ranging and controversial treatment programme by 9%, to US$112mn. Brazil is one of the worst hit countries in Latin America, accounting for an estimated 57% of all cases of HIV/AIDS in the region. Brazil's HIV/AIDS programme covers some 160,000 people and utilises a total of 17 drugs, seven of which are still under patent.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct